81710
L-脯氨酸
≥99.0% (NT)
别名:
( S )-吡咯烷-2-羧酸
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C5H9NO2
化学文摘社编号:
分子量:
115.13
Beilstein:
80810
EC 号:
MDL编号:
UNSPSC代码:
12352209
eCl@ss:
32160406
PubChem化学物质编号:
方案
≥99.0% (NT)
表单
crystalline powder
旋光性
[α]20/D −84.5±1°, c = 5% in H2O
杂质
≤0.3% foreign amino acids
灼烧残渣
≤0.1% (as SO4)
缺失
≤0.2% loss on drying, 110 °C
颜色
white
mp
228 °C (dec.) (lit.)
痕量阴离子
chloride (Cl-): ≤100 mg/kg
sulfate (SO42-): ≤100 mg/kg
痕量阳离子
Ca: ≤10 mg/kg
Cd: ≤5 mg/kg
Co: ≤5 mg/kg
Cr: ≤5 mg/kg
Cu: ≤5 mg/kg
Fe: ≤5 mg/kg
K: ≤50 mg/kg
Mg: ≤5 mg/kg
Mn: ≤5 mg/kg
NH4+: ≤20 mg/kg
Na: ≤50 mg/kg
Ni: ≤5 mg/kg
Pb: ≤5 mg/kg
Zn: ≤5 mg/kg
SMILES字符串
OC(=O)[C@@H]1CCCN1
InChI
1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1
InChI key
ONIBWKKTOPOVIA-BYPYZUCNSA-N
正在寻找类似产品? 访问 产品对比指南
其他说明
脯氨酸催化的不对称 Robinson 环化;β-紫罗兰叉乙醛、视黄醛和相关化合物的不对称自缩合反应
储存分类代码
11 - Combustible Solids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
C. Agami et al.
Journal of the Chemical Society. Chemical Communications, 418-418 (1984)
A.E. Asato et al.
Tetrahedron Letters, 33, 3105-3105 (1992)
Marie Couturier et al.
The Journal of biological chemistry, 288(20), 14624-14635 (2013-04-06)
The microbial deconstruction of the plant cell wall is a key biological process that is of increasing importance with the development of a sustainable biofuel industry. The glycoside hydrolase families GH5 (PaMan5A) and GH26 (PaMan26A) endo-β-1,4-mannanases from the coprophilic ascomycete
Michael P Manns et al.
Gastroenterology, 147(2), 366-376 (2014-04-15)
MK-5172 is an inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A protease; MK-5172 is taken once daily and has a higher potency and barrier to resistance than licensed protease inhibitors. We investigated the efficacy and tolerability of MK-5172
David Saadoun et al.
Annals of the rheumatic diseases, 73(5), 831-837 (2013-04-23)
The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination. To analyse the safety and efficacy of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持